Last updated: August 4, 2025
Introduction
Japan Patent JP2013515041, titled "Method for producing a pharmaceutical composition comprising a statin", pertains to a novel process for manufacturing pharmaceutical compositions, specifically those containing statins. Statins are widely prescribed lipid-lowering agents essential for managing hypercholesterolemia and cardiovascular risk. Understanding this patent's scope and claims, along with its position within the patent landscape, informs strategic decisions for stakeholders operating within the pharmaceutical and biotech sectors.
Scope of Patent JP2013515041
JP2013515041 broadly covers a proprietary method for producing statin-containing pharmaceutical compositions with improved stability, bioavailability, or manufacturing efficiency. The patent's scope hinges on specific process steps, formulations, and possibly intermediates involved in synthesizing or combining active pharmaceutical ingredients (APIs) with excipients.
The scope is niché but critical, aiming to carve a niche in manufacturing efficiencies or product stability rather than claiming a new chemical entity. This approach aligns with many process patents in pharma, which often focus on methods that optimize existing drugs.
Claims Analysis
1. Core Claims
The primary claims of JP2013515041 target the process of producing a statin formulation with specific parameters:
-
Claim 1: Details a process comprising specific steps such as pharmaceutical compound preparation, specific temperature regimes, solvent selection, and control of pH during synthesis. This independent claim establishes the fundamental patentable process.
-
Claim 2 and Subsequent Claims: These depend on Claim 1, adding limitations like specific solvent types (e.g., ethanol, water), types of statin (e.g., atorvastatin, rosuvastatin), and process conditions (pressure, mixing times). They may also cover the use of particular excipients or stabilizers.
2. Scope of the Claims
The claims are likely narrow, focusing on particular process parameters rather than broad composition claims. This allows for tailored protection against process imitators but limits broader product protection. For instance, the patent probably does not claim the statin compound itself but the manufacturing method tailored to produce a specific formulation with desired qualities.
3. Potential Claim Limitations
-
Process specificity: Precise temperature ranges, solvents, or pH levels limit the claim scope but strengthen enforcement against infringing processes deviating from these conditions.
-
Formulation parameters: Claims involving specific excipient combinations, particle sizes, or stability-enhancing steps augment the patent’s protection, especially against process-based challenges.
4. Claims of Priority or Related Applications
The patent might benefit from priority claims to earlier applications, enhancing its scope, especially if filed prior to other similar patents. Cross-referencing with related patents can expand or constrain its scope.
Patent Landscape and Positioning
1. Comparative Position within the Patent Environment
Japan’s pharmaceutical patent landscape is highly dynamic, with over 20,000 patents filed annually in the biotech and pharma sector. Key players like Takeda, Astellas, and Chugai actively pursue process patents akin to JP2013515041, primarily focusing on optimizing existing statins and enhancing formulation stability[1].
2. Prior Art and Overlapping Technologies
Prior art relevant to this patent includes earlier process patents on statin formulations, such as:
JP2013515041 distinguishes itself through tailored process parameters, perhaps providing advantages like higher yield or better stability profiles.
3. Patent Families and International Coverage
While this patent is specific to Japan, similar process patents are often filed internationally, including in the US and Europe. The absence of corresponding patents elsewhere could limit the global enforceability but also illustrates Japan’s strategic focus on local manufacturing improvements.
4. Competitive Landscape
Competitors are likely to have developed alternative manufacturing processes or formulations. The patent’s narrow claims may render it susceptible to design-around strategies. Conversely, the process's unique aspects could inhibit competitors from copying without infringement if the claims are robust.
5. Patent Duration and Market Implications
Filed around 2013, the patent’s expiry is expected around 2033—assuming standard 20-year terms—and remains an essential window for exclusivity in Japan. As patent protection wanes, generic manufacturers could introduce competing products or processes, affecting market share.
Implications for Stakeholders
-
Pharmaceutical Companies: The process protected by JP2013515041 enables manufacturing of statin formulations with enhanced qualities, potentially providing a competitive advantage in the Japanese market.
-
Generic Manufacturers: Need to analyze whether alternative processes infringe this patent or if designing around its specific process claims can avoid infringement.
-
Patent Portfolio Strategists: Should consider filing corresponding patents internationally or strengthening claims through continuation applications targeting broader process scopes.
Conclusion
JP2013515041 exemplifies a targeted process patent within Japan’s pharmaceutical innovation framework. Its claims focus on manufacturing steps designed to optimize statin production, offering critical protection for patent holders while delineating clear boundaries for potential infringers. The patent is well-positioned within a landscape of similar process-oriented filings, underscoring Japan's emphasis on manufacturing efficiencies and quality in pharmaceutical development.
Key Takeaways
-
Narrow but Strategic Claims: Emphasize specific process steps, offering strong protection against direct copying but requiring vigilant monitoring for alternatives.
-
Competitive Landscape: Similar process patents exist; differentiating features in manufacturing processes are vital for enforceability and market exclusivity.
-
International Considerations: To maximize protection, filing corresponding patents globally is advisable, especially in markets with significant statin use.
-
Patent Expiry: Expected around 2033; post-expiry, generics will gain entry unless supplementary patents or data exclusivity apply.
-
Business Strategy: Innovate process parameters further or combine with formulation patents to strengthen overall patent portfolio.
FAQs
1. What type of patent is JP2013515041—composition or process?
It is a process patent focusing on the manufacturing method of statin pharmaceutical compositions.
2. Does this patent protect the chemical structure of statins?
No; it does not claim the statin molecules themselves but the process for producing formulations containing statins.
3. Can generic manufacturers circumvent this patent?
Yes, by developing alternative manufacturing processes that do not infringe on the specific steps claimed in the patent.
4. How does this patent impact the Japanese market?
It gives the patent holder exclusive rights to manufacture and sell specific statin formulations in Japan, potentially affecting pricing and availability.
5. Are there similar patents internationally?
Likely, but patent families or equivalents would need to be analyzed for comprehensive protection outside Japan.
Sources:
[1] Japan Patent Office, Annual Patent Filing Reports.
